1. Introduction {#sec1-1}
===============

Depression is a clinically common form of mental illness characterized by depressive mood and / or loss of interest and accompanied by mental disease with somatic and neurophysiological symptoms.^\[[@ref1]\]^ WHO reports that depression is one of the major risk factors for years of disability.^\[[@ref2]\]^ It is predicted that by 2020, depression will jump from 4th place to the 2nd leading cause of global burden of disease.^\[[@ref3]\]^ The pathogenesis of depression in not yet clear, and the treatment for depression is still mainly pharmaceutical; however, many patients treated with pharmacotherapy do achieve ideal outcomes. There still remains a significant portion of patients (20%-30%) who despite having received sufficient dosage and completed the prescribed course of treatment still do not see a total alleviation of depressive symptoms. Although new antidepressants continue to emerge, the side effects of medication therapy are still not completely avoidable.^\[[@ref5]\]^

With the development of imagining technology, research findings show that patients with depression may have organic brain damage. This phenomenon indicates that the pathology of depression is probably related to organic brain damage. Fortunately, thanks to the introduction of a series new techniques in neural modulation, advancements have been made in the treatment of depression. Among these modulation techniques is repetitive transcranial magnetic stimulation (rTMS). Developed in the mid 1980s, the technique is a bio-stimulation that affects and changes the function of the brain. By making use of the time varying magnetic field to act on the cerebral cortex and creating an induced current in the cerebral cortex that alters the action potential of cortical neurons, rTMS is a biological stimulation that affects brain metabolism and neuronal electrical activity. Based on the mechanism of TMS, the induced pulses of current can depolarize neurons and when applied repetitively (an approach known as rTMS) can modulate cortical excitability through altering the parameters of stimulation^\[[@ref6]\]^ to repair white brain matter or neurologic damage, thus attaining therapeutic effects.

Repetitive transcranial magnetic stimulation can be divided into high-frequency stimulation (5-20Hz) and low-frequency stimulation (≤1Hz). Depending on the frequency, the high frequencies can increase cortical excitability, and the low-frequency suppresses excitability.^\[[@ref7]\]^ Recently, rTMS and fMRI (functional magnetic resonance image, fMRI) were combined to identify cognitive-related brain areas ^\[[@ref8]\]^ responsible for executing cognitive tasks. And with the development of technology, deep transcranial magnetic stimulation has gradually become an effective treatment for mental illness^\[[@ref11],[@ref12]\]^ Repetitive transcranial magnetic stimulation has been shown to be effective for the treatment of affective disorders such as depression in many randomized controlled studies,^\[[@ref13]\]^ but most of the sample size in these studies was relatively small. As a result, general consistent conclusions cannot be drawn across these studies.^\[[@ref14]\]^ Clinicians and patients believe that rTMS is a way to treat depression, but there is still a need for more evidence to support the determination of optimal parameter settings for treating depression. Thus, in this study, we compare the efficacy of antidepressants combined with rTMS treatment versus sham controlled rTMS in treating patients with depression.

2. Methods {#sec1-2}
==========

2.1 Literature screening and retrieval strategy {#sec2-1}
-----------------------------------------------

In this study, we used the keywords: "抑郁"(depression) and "经颅磁刺激"(TMS) to retrieve articles from the Chinese databases: Chinese National Knowledge infrastructure (CNKI), Wang Fang Data, and China Science and Technology Journal Database (CSTJ); and used the keywords: "depress\*", "transcranial magnetic stimulation", "TMS", "rTMS" to retrieve from the following English language databases: Embase, PubMed, the Cochrane Library, Web of Science, PsycInfo. We searched for Randomized Control Trials (RCTS) that study the efficacy and safety of rTMS in the treatment of depression, with the date of publication on or before 5 January 2017.

2.2 Inclusion and exclusion criteria {#sec2-2}
------------------------------------

This study included the randomized sham controlled studies of the efficacy and safety of RTMS in the treatment of depression and evaluated the efficacy and safety of the combination of RTMS and antidepressants in the treatment of depression.

### 2.2.1 Objective of study {#sec3-1}

All subjects that participated in the study groups were classified according to one of the following psychiatric diagnostic standards: International Classification of Diseases (ICD) ^\[[@ref15]\]^, Diagnostic and Statistical Manual of Mental Disorders (DSM) ^\[[@ref16]\]^, or the third edition of the Chinese Mental Illness Diagnostic Standard (CCMD-3).^\[[@ref17]\]^

### 2.2.2 Included study types {#sec3-2}

The included studies were randomized controlled trials in which the study group used rTMS intervention and the control group used rTMS sham coils or flipped stimulation coils at a certain angle to achieve the sham stimulus effect. In the outcome, the extent of improvement and side effects in the patients with depression was measured. The research program design types are as follows: ① left high frequency stimulation VS. left high frequency sham stimulation; ② right low frequency stimulation VS right low frequency sham stimulation; ③ left high frequency stimulation (combined with medication treatment) VS left high frequency pseudo-stimulation (combined with medication treatment); ④ right low-frequency stimulation (combined with medication treatment) VS right low-frequency sham stimulation (combined with medication treatment / psychotherapy).

### 2.2.3 Exclusion criteria {#sec3-3}

Studies with the following contents were excluded:

\(1\) Experimental studies using animals; (2) senile depression, postpartum depression, post-traumatic stress disorder with depression; (3) review and case report studies; (4) repeatedly published studies; (5) improvement of non-depressive symptoms, such as, changes in cortical excitability, change in cerebral hemodynamic characteristics, or cognitive functions etc. at treatment outcome as the primary outcome indicators; (6) using blank control as controlled group or studies involving electroconvulsive therapy; (7) studies with unspecified randomization methods and cross-sectional design were excluded.

2.3 Literature screening and data extraction {#sec2-3}
--------------------------------------------

Two researchers used the same inclusion and exclusion criteria to screen the literature retrieved from the electronic databases. We used the following screen and extraction process: (1) Check for duplicates from the retrieved articles. (2) Titles and abstracts of the retrieved articles were separately screened by two researchers to exclude those articles unrelated to this study. (3) the full text of remaining articles was read to further screen out articles according to listed inclusion and exclusion criteria. (4) Any disagreements about whether articles shoul be included or excluded were discussed among the two researchers, in the case where no consensus could be reached, a third senior research was consulted to make the final determination (see [Figure 1](#fig001){ref-type="fig"} for study flowchart). The included information extraction form was developed by Wei Yanyan. The two researchers extracted the research data separately, and the extracted information included categories such as study authors, year of publication, sample size, true stimulus frequency, stimulus site, stimulus intensity (% of resting motor threshold), sham stimulation mode, and treatment cycle.

2.4 Risk of Bias assessment {#sec2-4}
---------------------------

A risk of bias assessment was carried out for all RCTs included in this study according to the guidelines put forth by the Cochrane Collaboration Network. The assessment mainly includes the following seven aspects: (1) random sequence generation (selection bias); (2) allocation concealment (selection bias); (3) Blinding of the subjects and the researcher (implementation bias); (4) Blindness of measurement of outcomes (measurement bias); (5) Integrity of the results (attribution bias); (6) Selective reporting of outcomes (reporting bias); (7) Other bias. All risky information included in this study was evaluated separately by two investigators and was discussed and agreed to by a third researcher in cases of disagreement.

2.5 Outcome Measures {#sec2-5}
--------------------

Primary outcome measures: Assessment of efficacy of rTMS in treating the depressive symptoms of patients with depression

The outcome measures included in this study were score assigned with 1st priority in the study: Hamilton Depression Rating Scale (HDRS) scores measured before and after the intervention, Montgomery Asberg Depression Rating Scale (MADRS) score before and after the intervention of rTMS as the second priority score, and Beck Depression Inventory (BDI) score change before and after rTMS intervention as the third priority score.

Secondary Outcome Measures: Improvement in overall function, side effects, safety, and tolerability of treatment.

To assess the improvement of overall function of patients with depression after rTMS intervention, we used mainly the scores of Brief Psychiatric Rating Scale (BPRS) and Global Assessment of Functioning (GAF) scores to calibrate the change. Safety was assessed by comparing the differences in adverse reactions between the two groups. The comparison included the general adverse reactions such as headache, nausea, and insomnia and serious adverse reactions such as epilepsy. The acceptability of rTMS treatment was compared by the dropout rate between the two groups during the treatment courses.

2.6 Statistical Analysis {#sec2-6}
------------------------

Data were analyzed using the Revman 5.3 statistical software, and heterogeneity was assessed using the χ^2^ test. When all studies met the statistical homogeneity (*p\>* 0.1, *I^2^* \<50%), we used the fixed effects model for Meta-analysis of the treatment effect and side effects; otherwise, we employed the random effects model for Meta-analysis and took the source of heterogeneity into consideration. For the combined effect analysis, we used Standardized Mean Deviation (SMD), Relative Risk (RR) and its 95% CI. The final calculated result was shown in the Forest Plot. Cochrane was used for risk assessment and funnel plot for observing publication bias. At the same time, Stata12.0 linear regression method was designated to detect funnel chart symmetry.

3. Results {#sec1-3}
==========

3.1 Literature screening process {#sec2-7}
--------------------------------

Using the search strategy specified in above, we retrieved from 5 English databases and 3 Chinese databases a total of 9798 related articles. Endnote Document Management Software was used for exclusion screening, and the following studies were excluded based on the following: duplicate study- 4,125 studies; articles with irrelevant research purposes- 4,849 studies; did not meet inclusion criteria- 824 studies; unknown process in grouping or without randomized sham controlled trials- 45 studies; and repeatedly published- 2 studies^\[[@ref18],[@ref19]\]^ and duplicate reports from the results of 2 master's theses.^\[[@ref20],[@ref21]\]^ In addition, a study was excluded because only the lowest, highest, and median scores for the Hamilton Depression Inventory score for TMS interventions were given, leaving the mean and standard deviation unspecified as well as the side effects and dropout rate unreported.^\[[@ref22]\]^ In the end 29 articles were included in this systematic review.^\[[@ref18],[@ref23]\]^

3.2 Characteristics of included studies {#sec2-8}
---------------------------------------

All subjects included in this study were diagnosed with depression with one of the following diagnostic criteria: DSM-IV, CCMD-3, or ICD-10. Three studies were with the subjects that met the diagnostic criteria for refractory depression, and in many cases, the parameters setting in the rTMS treatment were the high-frequency stimulus applied on the left hemisphere. Four of the studies used 1 Hz of low-frequency stimulus over the right hemisphere,^\[[@ref24],[@ref28],[@ref31],[@ref43]\]^ and in a 2010 article, the stimulus frequency 5 Hz and 20 Hz were utilized alternately to perform interventions,^\[[@ref26]\]^ but to reach equilibrium with the sham controlled group, the subjects included in the sham control were also equally distributed using the frequencies of 5 Hz and 20 Hz. In Xie et al. (2015) 30% resting motor threshold was used, the intensity of the stimulation in all other studies was controlled within the range of 80%-120% of resting motor threshold. In all the included studies, the shortest treatment period was 2 weeks, and the longest was 8 weeks. Twelve studies used sham coil as a means ^\[[@ref18],[@ref29],[@ref31],[@ref44],[@ref46],[@ref47],[@ref49],[@ref50]\]^ to setup the sham controlled group; in the remaining studies, the coil was rotated 45, 90, or 180 degrees to achieve the effect of sham therapy, but in George et al., how the sham stimulus control was achieved was not specified.^\[[@ref36]\]^ During the entire course of rTMS treatment, all subjects maintained the original type or dose of medication therapy or received a specific dose of medication therapy after a period of evaluation.

### 3.2.1 Quality of the included studies {#sec3-4}

In the literature screening process, the studies with unspecified conditions for randomized grouping or with high risk in random grouping were excluded; therefore, in quality assessment of the included studies (see [figure 2](#fig002){ref-type="fig"}), all the included studies were presented with conditions depicting the randomized grouping and were rated as "Low risk". Five studies qualified their randomized allocation concealment,^\[[@ref30],\ [@ref34]\]^ and the selection bias was rated as "Low risk." 11 studies used blind methodology with their experimenters and researchers^\[[@ref18],[@ref25],[@ref27],[@ref29],[@ref30],[@ref32],[@ref36],[@ref37],[@ref43]\]^ and performance bias was rated as "Low risk." One study was selective in reporting their results,^\[[@ref27]\]^ the reporting bias was rated as "High risk". Studies with unclear information were rated as having "Unclear risk". [Figure 3](#fig003){ref-type="fig"} is a funnel plot that incorporates the trials studying the efficacy of the therapy that uses medication combined with rTMS in the treatment of depression. The existence of an asymmetrical trend may due to publication bias or other causes.

3.3 Treatment effect {#sec2-9}
--------------------

Of the 29 included studies, the primary outcome measures were the Hamilton Depression Symptom Inventory (HAMD) score before and after the intervention with 6 studies using 21 items on the HAMD scale; 3 studies using 24 items on the HAMD scale; and the remaining studies using 17 items on the HAMD scale. The heterogeneity of the included studies was high (*χ^2^* = 293.24, *I^2^* = 90%); therefore, the random effects model was used for meta-analysis. The results show that efficacy of the rTMS combined with antidepressant therapy in treatment of depression is significantly higher than the sham stimulation group (SMD = -0.84, 95% CI: -1.19 ^\~^ -0.48), and the difference was statistically significant (Z = 4.65, *p*\< 0.01) See [Figure 4](#fig004){ref-type="fig"}. According to the GRADE score, as the main outcome measure, i.e. the improvement in symptoms of depression in rTMS interventions, the overall quality level of evidence is "moderate" as shown in [Table 2](#table002){ref-type="table"}.

3.4 Subgroup analysis {#sec2-10}
---------------------

According to the sites of stimulation (the left hemisphere and right hemisphere) the studies are divided into subgroups. The results of subgroup analysis were *χ^2^* = 518.84, *I^2^* = 96% and *χ^2^* = 7.65, *I^2^* = 48%. The heterogeneity results were *χ^2^* = 529.07, *I^2^* = 95%, *p*\<0.01 (see [Figure 5](#fig005){ref-type="fig"}), suggesting greater heterogeneity with the left hemisphere stimulation site. According to the administered frequencies of stimulation the studies were divided into two groups: a group with high-frequency stimulation \>1 Hz and a group with low-frequency stimulation ≤1Hz, and the sub-group analysis results were *χ^2^* = 489.56, *I^2^* = 95% and *χ^2^* = 7.65, and *I^2^*= 61% respectively. The combined heterogeneity results were *χ^2^* = 499.37 and *I^2^*= 94%, *p*\<0.01 (see [Figure 6](#fig006){ref-type="fig"}). Subgroup analyzes were performed according to the duration of the treatment course (i.e. treatment course ≤4 weeks and\> 4 weeks). The subgroup analysis results were *χ^2^* = 471.26, *I^2^*= 95% and *χ^2^* = 9.62, *I^2^* = 58% Post hoc heterogeneity resulted in *χ^2^* = 502.28, *I^2^*= 94%, *p* \<0.01 (see [Figure 7](#fig007){ref-type="fig"}). Subgroup analyzes were performed over the differences between studies published in Chinese-language journals and studies published in English-language journals. The subgroup analyzes showed *χ^2^* = 203.52, *I^2^* = 91%, *χ^2^* = 290.18, and *I^2^*= 97%, respectively. The combined heterogeneity was *χ^2^* = 499.37, *I^2^* = 94%, *p* \<0.01 (see [Figure 8](#fig008){ref-type="fig"}).

3.5 Heterogeneity Meta-regression {#sec2-11}
---------------------------------

Given that heterogeneity may be due to the differences in the severity, age, and prescript stimulations parameters of the subjects, linear regression was used to assess the relationship between heterogeneity and baseline depression, age of participants, and stimulation parameters. Baseline HAMD scores, intensity of stimulation, frequency of stimulation, and stimulation regimens were included as factors in the regression model to assess the effect on heterogeneity. Baseline HAMD scores and regression analysis of age alone showed P values of 0.993 and 0.142, suggesting that the severity and age of patients with baseline depression were not a contributing factor to heterogeneity. Then the stimulation intensity, stimulation frequency and stimulation treatment course were included in the regression model to get the *p* value of 0.052, 0.536 and 0.047 respectively. The intensity and stimulation treatment course may be related factors causing heterogeneity. Among the two factors, when the course of treatment was put into the regression model, that explained 12.8% of the variation in heterogeneity.

3.6 Meta-analysis of adverse reactions {#sec2-12}
--------------------------------------

None of the included studies reported serious adverse effects. Twenty of the studies reported their subjects experienced slight discomfort including: headache, pain in the stimulation site, muscle tension, dizziness, loss of interest et cetera. Of the 690 subjects in the true stimulation treatment group, 319 reported discomfort, and 108 of 663 subjects in the sham controlled group reported discomfort. The included studies were statistically homogenous (*χ^2^* = 25.60, *p*= 0.06, *I^2^*= 38%), thus a statistical analysis using the fixed effects model was performed. The results showed that rTMS combined with antidepressants in the treatment of depression has a higher incidence rate of side effects, RR = 1.96, 95% CI: 1.47 ^\~^ 2.61. ([Figure 9](#fig009){ref-type="fig"})

3.7 Meta-analysis of dropout rate {#sec2-13}
---------------------------------

Twelve included studies reported participant withdrawal, and meta-analysis of the withdrawal cases data was performed. The results showed good homogeneity among the studies (*χ^2^* = 6.76, *p* = 0.82, *I^2^*= 0), and were analyzed using the fixed effects model. There were no significant differences between the two groups (27 cases in the stimulus group and 22 cases in the sham controlled group), the difference was not statistically significant (RR = 1.27, 95% CI: 0.75-2.12, Z = 0.89).

4. Discussion {#sec1-4}
=============

4.1 Main findings {#sec2-14}
-----------------

Although pharmacotherapy is still the most commonly used treatment for depression, rTMS treatment for patients with refractory depression is an available option. The results of this study show that rTMS treatment of depression has a higher incidence rate of side effects, because the included studies use selfreporting methods to collect data on side effects from the subjects and seldom use scales for quantitative assessment. Also, the side effects disappeared shortly after treatment.

Although there are many meta-analyzes on the efficacy of rTMS in the treatment of depression, most of them are confined to the English literature. The present study focused on the efficacy of rTMS versus the sham control in the treatment of depressive symptoms. Compared with the previous meta-analyses, this study has larger sample size that consists of 29 studies and a total sample size of 1659 subjects and included Chinese literature, of which 10 studies were randomized controlled trials published in Chinese, and the sample size of 571 cases in these Chinese studies accounted for a certain percentage of the total sample size. The quality of evidence of GRADE for the primary outcome measure (treatment effect) was "moderate," and the study of rTMS in combination with drug therapy for depression requires further improvement in the quality of studies; side effects and dropout rates to show the acceptability of using rTMS to treat patients with depression.

4.2 Limitations {#sec2-15}
---------------

Although all enrolled studies employed randomized grouping and blind methods in evaluation, the study outcomes show that heterogeneity among the included studies was high. Heterogeneity was analyzed by using regression model and subgroup analysis, etc. The stimulus frequency, stimulus intensity and duration of treatment courses were set to the regression model, and the results showed that duration of the treatment course may be one of the factors causing heterogeneity. Similarly, there may be other factors, such as the subjects' course of disease and number of stimulus train, determining heterogeneity.

4.3 Implications {#sec2-16}
----------------

Treatment combined rTMS with antidepressants pharmacotherapy is an important option for clinicians in treating depression. Especially for some refractory cases of depression, rTMS is a feasible option for consideration. However, affecting the treatment, there are many parameters, such as the intensity of the stimulus, frequency of the stimulus train, the site for stimulation, or even the course of treatment. Testing and optimizing these parameters settings and as much as exploring the maintenance effect of rTMS after treatment still depends on the yet to come representative randomized clinical trials.
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###### 

Basic information of the included studies

  No   study              Diagnostic criteria   N(M/F)                  Age(M±SD)                Site for stimulation                     Frequency   Magnitude (%MT)   Course of therapy (week)   Sham stimulation   Combined with medication (Y/N)
  ---- ------------------ --------------------- ----------------------- ------------------------ ---------------------------------------- ----------- ----------------- -------------------------- ------------------ --------------------------------
  1    George 1997        DSM-IV                7(1/6) 42.4(15.47)      5(0/5) 41.0(8.28)        Left DLPFC                               20 Hz       90                4                          45^o^              Y
  2    Klein 1999         DSM-IV                36(7/29) 60.5(15.1)     34(10/24) 58.9(18.3)     Right prefrontal area                    1 Hz        110               2                          45^o^              Y
  3    Berman 2000        DSM-IV                10(8/2) 45.2(9.54)      10(6/4) 39.4(10.81)      Left DLPFC                               20 Hz       80                2                          45^o^              Y
  4    George 2000                              20(7/13) 42.2(10.8)     10(4/6) 48.5(8)          Left prefrontal cortex                   5/20 Hz     100               2                          45^o^              Y
  5    Garcia 2001        DSM-IV                11(5/6) 43.2(13.1)      11(5/6) 45.0(18.3)       Left DLPFC                               20 Hz       90                2                          90^o^              Y
  6    Kauffmann 2004     DSM-IV                5(NA) (NA)              7(NA) (NA)               5cm anterior to the Right Motor Cortex   1 Hz        110               2                          45^o^              Y
  7    Rumi 2005          DSM-IV                22(3/19) 39.3(12.8)     24(4/20) 38.9(8.8)       Left DLPFC                               5 Hz        120               4                          Sham coil          Y
  8    Avery 2006         DSM-IV                35(14/21) 26.2(12.3)    33(17/16) 25.4(11.7)     Left DLPFC                               10 Hz       110               3                          90^o^              Y
  9    Januel 2006        DSM-IV                11(2/9) 38.64(11.16)    16(4/12) 37.19(11.67)    Right DLPFC                              1Hz         90                4                          Sham coil          Y
  10   Loo 2007           DSM-IV                19(11/8) 45.7(15.0)     19(9/10) 49.8(2.5)       Left DLPFC                               10Hz        110               6                          Sham coil          Y
  11   Reardon 2007       DSM-IV                155(69/86) 47.9(11.0)   146(72/74) 48.7(10.6)    Left DLPFC                               10 Hz       120               6                          Sham coil          Y
  12   Mogg 2008          DSM-IV                29(13/16) 55(18.0)      30(9/21) 52(15.5)        Left DLPFC                               10 Hz       110               2                          Sham coil          Y
  13   Schutter 2009      DSM-IV                17(7/10) 44.4(11.8)     17(10/7) 43.8(12.5)      Right parietal cortex                    2 Hz        90                2                          Sham coil          Y
  14   George 2010        DSM-IV                92(34/58) 47.7(10.6)    98(36/62) 46.5(12.3)     Left prefrontal cortex                   10 Hz       120               2                          NA                 Y
  15   Lingeswaran 2011   DSM-IV                9(3/6) 34(10.5)         14(6/8) 37.2(11.8)       Left DLPFC                               10 Hz       100               2                          90^o^              Y
  16   Ray 2011           ICD-10                20(15/5) 36.75(12.27)   20(17/3) 31.25(9.28)     Left DLPFC                               10 Hz       90                2                          45^o^              Y
  17   Huang 2012         DSM-IV                28(9/19) 32.77(7.28)    28(8/20) 31.35(7.39)     Left DLPFC                               10 Hz       90                2                          90^o^              Y
  18   XIE 2015           ICD-10                35(12/23) 65.3(5.1)     26(8/18) 64.7(4.2)       Left DLPFC                               10Hz        **30**            4                          Mock-coil          Y
  19   Zhang 2011         DSM-IV                14(11/3) 50.8(13.3)     14(9/5) 43.8(13.9)       Left DLPFC                               10 Hz       110               4                          180^o^             Y
  20   Wang 2012          CCMD-3                20(15/5) 34.85(13.71)   20(14/6) 36.75(16.70)    Left DLPFC                               15 Hz       110               4                          180^o^             Y
  21   Li 2013            CCMD-3                15(9/6) NR              15(8/7) NR               Left DLPFC                               10 Hz       100               4                          90^o^              Y
  22   Wang 2013          DSM-IV                30(14/16) 37.68(8.13)   29(13/16) 38.13(7.79)    right DLPFC                              1 Hz        100               4                          90^o^              Y
  23   Fang 2014          DSM-IV                24(9/15) 41.63(11.02)   24(10/14) 44.58(12.36)   left DLPFC                               10 Hz       80                2                          Sham coil          Y
  24   Yuan 2014          DSM-IV                30(9/21) 34.81±9.74     30(11/19) 36.76±17.79    left DLPFC                               20 Hz       110               6                          Sham coil          Y
  25   Xu 2014            CCMD-3                30(16/14) 35.4(8.6)     30(15/15) 36.2(8.3)      left DLPFC                               10 Hz       80                6                          90^o^              Y
  26   Hu 2015            CCMD-3                35(20/15) 36.0(7.2)     35(19/16) 35.6(7.5)      left DLPFC                               1-20 Hz     80-110            4                          Sham coil          Y
  27   Shi 2015           ICD-10                42(19/23) NR            42(21/21) NR             left DLPFC                               10 Hz       100               4                          90^o^              Y
  28   Xiao 2015          ICD-10                30(12/18) 31.6(10.2)    30(11/19) 32.9(14.2)     left DLPFC                               10 Hz       80                4                          Sham coil          Y
  29   Liang 2016         DSM-IV                30(15/15) 36.60(5.75)   30(13/17) 36.45(5.71)    left DLPFC                               10 Hz       NA                8                          Sham coil          Y

**Remarks: N: number of subjects included in a study; M: Mean; SD:Standard deviation; DLPFC: Dorsolateral Prefrontal Cortex; MT: Motor Threshold; Y: Yes; N: No; NA: Not Applied**

###### 

GRADE quality of evidence assessment of individual outcome indicators for the efficacy of rTMS combined with antidepressant medication therapy in the treatment of depression

  Outcome indicator   No. of sample cases in the included studies   heterogeneity   Model of analysis   Group effect value    Estimated value   95% Confidence interval   GRADE quality of evidence                 
  ------------------- --------------------------------------------- --------------- ------------------- --------------------- ----------------- ------------------------- --------------------------- ------------- ----------
  Treatment effect    1659                                          90%             \<0.01              Random effect model   4.65              \<0.01                    0.84(SMD)                   -1.19,-0.48   Moderate
  Side effect         1353                                          38%             0.06                Fixed effect model    4.62              \<0.01                    1.96(RR)                    1.47,2.61     Moderate
  Drop-out rate       882                                           0%              0.82                Fixed effect model    0.89              0.37                      1.27(RR)                    0.75,2.12     Moderate

**SMD: standardized mean difference; RR: relative risk;**

**GRADE: The Grading of Recommendations Assessment, Development and Evaluation**
